Sagimet Announces Oral Presentation at the 8th Annual MASH Drug Development Summit

Core Insights - Sagimet Biosciences Inc. is a clinical-stage biopharmaceutical company focused on developing novel fatty acid synthase (FASN) inhibitors to address metabolic dysfunction and fibrotic pathways [1][3] - The company will present data on its lead drug candidate, denifanstat, at the 8th Annual MASH Drug Development Summit, highlighting its anti-fibrotic activity in metabolic dysfunction-associated steatohepatitis (MASH) [1][2] Company Overview - Sagimet is developing denifanstat, an oral, once-daily selective FASN inhibitor aimed at treating MASH, with positive results from the completed Phase 2b clinical trial (FASCINATE-2) [3] - The company targets diseases caused by the overproduction of the fatty acid palmitate [3] Industry Context - MASH is a severe liver disease affecting over 115 million people globally, with only one recently approved treatment in the U.S. and none in Europe [4] - The renaming of non-alcoholic fatty liver disease (NAFLD) to metabolic dysfunction-associated steatotic liver disease (MASLD) and nonalcoholic steatohepatitis (NASH) to MASH aims to reduce stigma and provide a clearer diagnosis [4]